Early Treatment of COVID-19 Pneumonia with Anakinra Guided by Urokinase Plasminogen Receptor
暂无分享,去创建一个
M. Netea | S. Ktena | G. Ippolito | E. Nicastri | G. Cavalli | L. Dagna | H. Milionis | A. Cingolani | M. Bassetti | I. Kalomenidis | C. Selmi | E. Giamarellos‐Bourboulis | F. Castelli | M. Doumas | K. Akinosoglou | K. Katrini | J. Eugen-Olsen | I. Bliziotis | M. Mouktaroudi | M. Fantoni | S. Metallidis | G. Dalekos | M. Kosmidou | P. Bakakos | G. Tzatzagou | G. Poulakou | Z. Alexiou | I. Papanikolaou | E. Giannitsioti | A. Rapti | M. Kyprianou | N. Gatselis | Spyridon Savvanis | P. Panagopoulos | I. Kainis | K. Dimakou | G. Tsoukalas | A. Argyraki | F. Serino | E. Kostis | G. Chrysos | M. Samarkos | A. Masgala | V. Kotsis | K. Tsiakos | C. Damoulari | D.-M. Myrodia | C. Cardellino | E. Kyriazopoulou | V. Tzavara | M. Chini | Antigone Kotsaki | V. Rapti | P. Koufargyris | M. Tsilika | G. Adamis | S. Symbardi | A. Fragkou | E. Katsigianni | Andrea Angeheben | K. Koliakou | S. Micha | Orestis Liatsis-Douvitsas | E. Florou | S. Savvanis
[1] I. Douglas,et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia , 2021, The New England journal of medicine.
[2] E. Vicaut,et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial , 2021, The Lancet Respiratory Medicine.
[3] M. Jaeger,et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study , 2020, Critical Care.
[4] T. Kohlsdorf,et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients , 2020, The Journal of experimental medicine.
[5] M. Cesari,et al. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study , 2020, Journal of Allergy and Clinical Immunology.
[6] I. Al-Zakwani,et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study , 2020, International Journal of Infectious Diseases.
[7] S. Loosen,et al. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. , 2020, Journal of the American Society of Nephrology : JASN.
[8] C. Dinarello,et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19 , 2020, Proceedings of the National Academy of Sciences.
[9] G. Chatellier,et al. Anakinra for severe forms of COVID-19: a cohort study , 2020, The Lancet Rheumatology.
[10] N. Rovina,et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia , 2020, Critical Care.